Dealmaking goes from mega to mini

The mega-merger was so 2009. This year was the year of the mini-merger; of many mini-mergers, in fact. As drugmakers continued their scramble to replace revenues lost or soon-to-be-lost to generic competition, they made their deals in sips and nibbles. Think cocktail party rather than sit-down, seven-course meal; a few hundred million or a couple billion dollars rather than $50 billion.

Of course, one of the reasons pharma went for smaller deals this year was because they're easier to digest. So while Pfizer ($PFE) and Merck ($MRK) and Roche worked to integrate Wyeth and Schering-Plough and Genentech ($DNA), respectively, Sanofi-Aventis ($SNY) snapped up the U.S. consumer products company Chattem for $1.9 billion and a Chinese consumer drugs company for $520 million. Biovail ($BVF) and Valeant Pharmaceuticals ($VRX) merged in a $3.2 billion deal. Japan's Astellas Pharma bought OSI Pharmaceuticals for $4 billion. GlaxoSmithKline ($GSK) nibbled on one emerging-markets company after another. And Pfizer re-entered the deal fray to offer $3.2 billion for pain-drug specialist King Pharmaceuticals.

The year's biggest deal--Novartis' ($NVS) majority-stake buyout of Alcon ($ACL)--was almost the exception that proved the rule. The company spent $28.1 billion to bring its stake in the eye care company to 77 percent, and in mid-December finally wrapped up an agreement to buy the remaining 23 percent for $12.9 billion. All told, that buyout cost more than $50 billion, and it will have taken almost two years from start to finish. Not a bite-sized endeavor at all.

Indeed, all you have to do to appreciate the virtues of the mini-merger is talk to Claudio Bergamo, CEO of Brazil's Hypermarcas, which just bought fellow Brazilian drugmaker for $1.5 billion. That's a big deal for Hypermarcas; revenue-wise, it's proportionate to combining, say, GlaxoSmithKline with Amgen ($AMGN). "It is like a boa after eating a cow," Bergamo said at the time. "It needs some time to digest." Months curled up in a tree, most likely. These days, drugmakers prefer to eat and run.

Suggested Articles

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.